Pharmacologic Management of Neuropsychiatric Symptoms in Dementia
Neuropsychiatric symptoms (NPS) are a core feature of all dementias and often exert a greater influence on clinical outcomes — including care partner burden, functional decline, and long-term placement — than cognitive symptoms alone. Over the disease course, nearly all patients with dementia experience one or more neuropsychiatric symptoms, including depression, anxiety, apathy, agitation, psychosis, and sleep disturbances. Although nonpharmacologic approaches remain first-line, pharmacologic therapy is frequently necessary when behavioral interventions are insufficient. Very few medications carry FDA approval for NPS in dementia, and treatment is largely empiric. This topic provides a comprehensive, evidence-based approach to pharmacologic management with attention to dosing, trial evidence, safety concerns, and dementia-type-specific considerations.
Bottom Line
- Start low, go slow: Patients with dementia are older and more susceptible to adverse effects — initiate at the lowest usual dose (or half) and titrate gradually over weeks to months
- SSRIs first for mood and agitation: Escitalopram, citalopram, and sertraline are the most commonly used psychotropics for NPS; citalopram (CitAD trial) and escitalopram (S-CitAD trial) have evidence for agitation without psychosis
- Brexpiprazole (2023): First and only FDA-approved antipsychotic specifically for agitation in Alzheimer disease dementia; the boxed warning for mortality still applies
- All antipsychotics carry an FDA boxed warning for increased mortality (~1.6–1.7× placebo) and cerebrovascular events in elderly patients with dementia
- Lewy body disease: Patients are extremely sensitive to antipsychotics — avoid D2-blocking agents; pimavanserin (FDA-approved for PD psychosis) or very-low-dose quetiapine are the safest options
- Methylphenidate has the strongest evidence for apathy in AD dementia (ADMET 2 trial)
- Dextromethorphan/quinidine is FDA-approved (2010) for pseudobulbar affect
- Reassess regularly: Attempt to taper psychotropic medications — especially antipsychotics — after symptom stability
FDA Boxed Warning — Antipsychotics in Elderly Patients with Dementia
- The FDA has issued a boxed warning for all antipsychotics (typical and atypical) used in elderly patients with dementia-related psychosis or agitation
- Associated with an increased risk of death (approximately 1.6–1.7× the rate in placebo-treated patients) in meta-analyses of placebo-controlled trials
- Increased risk of cerebrovascular adverse events (stroke, TIA), particularly with risperidone and olanzapine
- Short-term: sedation, orthostatic hypotension, falls; medium-term (months): weight gain, metabolic syndrome, extrapyramidal symptoms; long-term (years): cardiac arrhythmias, early mortality
- This warning applies even to brexpiprazole, the only antipsychotic with FDA approval for agitation in AD dementia
- Duration of antipsychotic use is closely monitored in care facilities; clinicians must discuss risks and benefits with patients and care partners
General Principles
Before initiating psychotropic medications, clinicians should ensure behavioral triggers have been assessed, environmental modifications attempted, and care partner education provided. For AD dementia specifically, optimizing cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine is recommended first, as these agents reduce overall NPS burden including apathy, agitation, and psychosis. Rivastigmine is also approved for Parkinson disease dementia and benefits neuropsychiatric symptoms in that condition.
Prescribing Framework for NPS in Dementia
- Step 1: Optimize cholinesterase inhibitors ± memantine (for AD) before adding psychotropics
- Step 2: Identify the predominant symptom cluster (mood, psychosis, agitation, apathy, sleep) and select medications accordingly
- Step 3: Choose agents that address multiple coexisting symptoms (e.g., mirtazapine for depression + insomnia; citalopram for anxiety + agitation)
- Step 4: Monitor systematically using validated scales (NPI-Q, PHQ-9, Cohen-Mansfield Agitation Inventory)
- Step 5: Reassess periodically and attempt taper, especially for antipsychotics and benzodiazepines
- Urgent situations: When a patient poses imminent risk of harm, more aggressive titration is warranted — consider inpatient geriatric psychiatry for rapid, safe stabilization
Antidepressants
Selective Serotonin Reuptake Inhibitors (SSRIs)
SSRIs are the most commonly used psychotropic class for NPS in dementia. Escitalopram, citalopram, and sertraline are preferred. Fluoxetine is used less frequently, and paroxetine is generally avoided because of its anticholinergic properties. Citalopram (CitAD trial, JAMA 2014) and escitalopram (S-CitAD trial) have both demonstrated efficacy for agitation in AD dementia, making them preferred over antipsychotics for agitation not associated with psychotic features. However, SSRIs may worsen apathy — a common coexisting symptom that must be monitored. Dose-dependent QTc prolongation with citalopram and escitalopram requires baseline ECG and a dose ceiling of ≤30 mg/day for citalopram in the elderly.
Other Antidepressants
Bupropion (75–300 mg/day) is a dual norepinephrine/dopamine reuptake inhibitor with an activating profile, making it useful for depression with prominent apathy. Mirtazapine (7.5–45 mg/day) has dose-dependent effects: at low doses (7.5–15 mg) it primarily targets histamine receptors producing sedation and appetite stimulation (useful for insomnia); at higher doses (30–45 mg) it provides antidepressant efficacy. Trazodone (50–200 mg/day) acts on multiple neurotransmitter systems and is used primarily as a sleep aid at low doses. Its fast onset (30–60 minutes) also makes it useful for PRN agitation management.
Stimulants for Apathy
Apathy is one of the most common and difficult-to-treat NPS across all dementia types. Unlike depression, apathy is characterized by diminished motivation and emotional engagement without subjective distress. SSRIs may worsen apathy, necessitating alternative approaches.
ADMET 2 Trial — Methylphenidate for Apathy in AD
- Design: Randomized, double-blind, placebo-controlled, multicenter trial (Mintzer et al., JAMA Neurol 2021)
- Population: Patients with AD dementia and clinically significant apathy
- Intervention: Methylphenidate (target dose 20 mg/day) vs placebo for 6 months
- Results: Improvement in apathy (NPI apathy subscale) and global functioning (ADCS-CGIC)
- Dosing in practice: 5–45 mg/day; start at 5 mg each morning and titrate gradually
- Side effects: Insomnia, appetite loss, increased blood pressure and heart rate
- Alternative: Amphetamine/dextroamphetamine (10–30 mg/day) has less trial evidence
Mood Stabilizers, Anxiolytics, and Other Agents
Lamotrigine (50–200 mg/day) is the best-tolerated mood stabilizer but requires slow titration over 6–8 weeks to minimize the risk of Stevens-Johnson syndrome. Valproic acid/divalproex (250–1000 mg/day) has faster onset (30–60 minutes) for acute management but carries more side effects (hyperammonemia, hepatotoxicity, thrombocytopenia) and limited evidence for dementia agitation. Gabapentin (300–900 mg/day) can be titrated more quickly but may be overly sedating. Buspirone (5–45 mg/day) is the preferred anxiolytic for chronic anxiety in dementia — it does not impair cognition and has no dependence potential, but requires weeks to reach efficacy.
Benzodiazepines in Dementia — Significant Risks
- Benzodiazepines may be used for short-term extreme anxiety, acute insomnia, or severe agitation, but carry significant risks in elderly patients with dementia
- Cognitive worsening: Can cause acute confusion or delirium (usually short-lived over several hours)
- Paradoxical reactions: Disinhibition and worsening agitation may occur
- Preferred agents if needed: Lorazepam (0.5–2 mg/day) and clonazepam (0.25–1 mg/day) — not as long-acting as diazepam, not as rapidly acting as alprazolam, and therefore less prone to dependence
- Avoid: Diazepam (long half-life, active metabolites) and alprazolam (rapid onset, high dependence risk)
- Limit use to the shortest course possible and reassess frequently
Antipsychotics
Antipsychotics are reserved for psychotic symptoms (delusions, hallucinations) and severe agitation, particularly when these symptoms pose safety risks. While effective, they carry the most significant safety concerns of any psychotropic class in dementia (see boxed warning above).
| Antipsychotic | Dose Range | D2 Affinity | Primary Use in Dementia | Key Side Effects | Notes |
|---|---|---|---|---|---|
| Quetiapine | 25–200 mg/d | Low | Psychosis, agitation, insomnia | Drowsiness, weight gain, orthostatic hypotension | Often first-line; low EPS risk; sedating |
| Risperidone | 0.5–2 mg/d | High | Psychosis, agitation | GI, dizziness, EPS (dose-dependent) | Keep dose low; EPS increases at higher doses |
| Olanzapine | 2.5–10 mg/d | Moderate | Psychosis, agitation | Weight gain, metabolic syndrome, EPS | Avoid in LBD (58% neuroleptic sensitivity) |
| Aripiprazole | 2–15 mg/d | Partial agonist | Psychosis, agitation | Akathisia, drowsiness, dizziness | Akathisia may mimic worsening agitation |
| Brexpiprazole | 0.5–3 mg/d | Partial agonist | Agitation in AD (FDA 2023) | Drowsiness, dizziness, headache, weight gain | First FDA-approved for AD agitation; boxed warning applies |
| Pimavanserin | 34 mg/d (fixed) | None | PD psychosis (FDA 2016) | GI, gait disturbance, QTc prolongation | 5-HT2A inverse agonist; no D2 blockade; safe for motor symptoms |
Brexpiprazole — Landmark FDA Approval
In 2023, the FDA approved brexpiprazole (Rexulti) for the treatment of agitation associated with Alzheimer disease dementia, making it the first and only antipsychotic with this specific indication. The pivotal randomized clinical trial (Lee et al., JAMA Neurol 2023) demonstrated statistically significant reduction in agitation scores compared with placebo. Brexpiprazole has partial agonist activity at dopamine D2 and serotonin 5-HT1A receptors and antagonist activity at 5-HT2A receptors. Dosing begins at 0.5 mg/day and is titrated to a target of 2–3 mg/day. Despite FDA approval, the boxed warning for increased mortality still applies, and the decision to prescribe requires careful risk-benefit discussion with care partners.
Pimavanserin — Parkinson Disease Psychosis
Pimavanserin is a selective serotonin 5-HT2A inverse agonist/antagonist approved in 2016 for hallucinations and delusions associated with Parkinson disease psychosis. Its key advantage is the absence of dopamine receptor blocking activity, meaning it does not worsen motor symptoms — critical in PD and LBD. Fixed dose of 34 mg/day. QTc prolongation must be monitored.
Neuroleptic Sensitivity in Lewy Body Disease
- Patients with Lewy body disease (DLB and PDD) are extremely sensitive to antipsychotics — avoid whenever possible
- Even low doses of D2-blocking antipsychotics can precipitate severe rigidity, immobility, obtundation, neuroleptic malignant syndrome-like reactions, and accelerated cognitive decline
- Neuroleptic sensitivity reactions occur in 30–50% of patients with DLB and can be life-threatening
- Olanzapine: 58% neuroleptic sensitivity frequency — should generally be avoided in LBD
- Classic neuroleptics (haloperidol, chlorpromazine) are contraindicated — highest risk of severe, potentially fatal reactions
- If absolutely necessary: pimavanserin (no D2 blockade) for PD psychosis; quetiapine (low D2 affinity) at very low doses (12.5–25 mg); clozapine (very low D2) is effective but requires ANC monitoring for agranulocytosis
Dextromethorphan/Quinidine for Pseudobulbar Affect
Pseudobulbar affect (PBA) is characterized by involuntary, frequent, and usually brief episodes of crying or laughing that are incongruent with the patient's emotional state. Dextromethorphan/quinidine (Nuedexta) was FDA-approved in 2010 for PBA. Dextromethorphan is an NMDA receptor antagonist that also inhibits serotonin reuptake; quinidine is a CYP2D6 inhibitor added to increase dextromethorphan bioavailability. Dosing is 20/10 mg twice daily. Side effects include dizziness, diarrhea, falls, and QTc prolongation.
Treatment Selection by Symptom Cluster and Dementia Type
| Symptom Cluster | First-Line | Second-Line | Key Considerations |
|---|---|---|---|
| Depression + anxiety | SSRI (escitalopram, citalopram, sertraline) | Mirtazapine; buspirone (add-on) | SSRIs may worsen apathy; QTc monitoring with citalopram/escitalopram |
| Depression + apathy | Bupropion | Methylphenidate (add-on); SSRI if mood predominates | Avoid SSRIs as sole agent when apathy is prominent |
| Apathy (primary) | Methylphenidate | Amphetamine/dextroamphetamine; bupropion | ADMET 2 supports methylphenidate; monitor cardiovascular parameters |
| Agitation without psychosis | SSRI (citalopram, escitalopram); brexpiprazole | Trazodone (PRN); mood stabilizer | SSRIs preferred over antipsychotics; brexpiprazole FDA-approved for AD |
| Agitation + psychosis | Quetiapine or risperidone (low dose) | Olanzapine; aripiprazole | Boxed warning applies; taper after stability; avoid in LBD |
| Psychosis in PD/LBD | Pimavanserin | Quetiapine (very low dose); clozapine | No D2 blockade with pimavanserin; avoid standard antipsychotics |
| Insomnia | Trazodone; mirtazapine (low dose) | Quetiapine (low dose); melatonin | Avoid chronic benzodiazepines; address sleep hygiene first |
| Pseudobulbar affect | Dextromethorphan/quinidine | SSRI | FDA-approved; distinguish PBA from mood-driven crying |
Dementia-Type-Specific Considerations
- Alzheimer disease: Optimize ChEI ± memantine before psychotropics; SSRIs for depression/anxiety/agitation; brexpiprazole for refractory agitation; methylphenidate for apathy
- Lewy body disease (DLB/PDD): Avoid D2-blocking antipsychotics whenever possible; pimavanserin for PD psychosis; quetiapine at very low doses if needed; rivastigmine has strongest evidence for cognitive and behavioral symptoms
- Frontotemporal dementia: SSRIs (especially sertraline, citalopram) for disinhibition, compulsive behaviors, and irritability; trazodone may help with agitation; antipsychotics have limited evidence
- Vascular dementia: Treat underlying cerebrovascular risk factors; SSRIs for depression and irritability; extra caution with antipsychotics given baseline cerebrovascular disease risk
Monitoring, Duration, and Tapering
| Medication Class | Key Monitoring | Duration & Tapering |
|---|---|---|
| SSRIs | GI symptoms (weeks 1–2); QTc (citalopram, escitalopram); apathy worsening | Continue while symptoms persist; gradual reduction over 2–4 weeks if resolving |
| Antipsychotics | Sedation, EPS, orthostatic BP, weight, glucose, lipids; QTc for pimavanserin | Shortest duration necessary; reduce 25–50% every 2–4 weeks after stability |
| Stimulants | Blood pressure, heart rate, weight, appetite, sleep | Continue while apathy persists; can be stopped relatively quickly |
| Benzodiazepines | Sedation, cognition, falls, paradoxical reactions | Shortest course possible; gradual taper (do not stop abruptly) |
| Mood stabilizers | LFTs, CBC, ammonia (valproate); rash (lamotrigine) | Continue if effective; gradual reduction with behavioral monitoring |
References
- Marshall GA. Neuropsychiatric symptoms in dementia. Continuum (Minneap Minn). 2024;30(6, Dementia):1744-1760.
- Lee D, Slomkowski M, Hefting N, et al. Brexpiprazole for the treatment of agitation in Alzheimer dementia: a randomized clinical trial. JAMA Neurol. 2023;80(12):1307-1316.
- Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA. 2014;311(7):682-691.
- Ehrhardt S, Porsteinsson AP, Munro CA, et al. Escitalopram for agitation in Alzheimer's disease (S-CitAD). Alzheimers Dement. 2019;15(11):1427-1436.
- Mintzer J, Lanctot KL, Scherer RW, et al. Effect of methylphenidate on apathy in patients with Alzheimer disease: the ADMET 2 randomized clinical trial. JAMA Neurol. 2021;78(11):1324-1332.
- Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693-702.
- Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533-540.
- Geldmacher DS. Treatment of Alzheimer disease. Continuum (Minneap Minn). 2024;30(6, Dementia):1823-1844.
- Galvin JE. Lewy body dementia. Continuum (Minneap Minn). 2024;30(6, Dementia):1673-1698.
- Mortby ME, Adler L, Aguera-Ortiz L, et al. Apathy as a treatment target in Alzheimer's disease: implications for clinical trials. Am J Geriatr Psychiatry. 2022;30(2):119-147.